Picture loading failed.

Pre-Made Ticilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Previously in development by Pfizer, it is now in investigation by MedImmune, a wholly owned subsidiary of AstraZeneca. It has been undergoing human trials for the treatment of various cancers but has not attained approval for any.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-569-1mg 1mg 3090
GMP-Bios-ab-569-10mg 10mg 21890
GMP-Bios-ab-569-100mg 100mg 148000
GMP-Bios-ab-569-xmg ＞100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Ticilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
INN Name Ticilimumab
TargetCTLA-4
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure5ggu:HL:AB/5ggv:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2005
Year Recommended2008
CompaniesAIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine
Conditions Approvedna
Conditions ActiveHead and neck cancer;Liver cancer;Mesothelioma;Non-small cell lung cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer
Conditions DiscontinuedDiffuse large B-cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes
Development TechAbgenix XenoMouse